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THE PARASYMPATHETIC NERVOUS SYSTEM
IN HUMAN HEART FAILURE

JESSICA A. FRENCH

ABSTRACT

Heart failure (HF) affects 5.8 million Americans and is characterized by an inability
of the heart to pump blood throughout the body. In a non-diseased state, the sympathetic
(SNS) and parasympathetic nervous systems (PNS) innervate the heart to regulate rate
and force of contraction. Actions of the PNS on the cardiovascular system are mediated
via the vagus nerve, releasing acetylcholine which binds muscarinic receptors on
cardiomyocytes. The SNS has been found to be overstimulated in HF, with the role of
the PNS in HF unclear. We hypothesized that the PNS is dysregulated in HF, resulting in
a change of muscarinic receptor densities. We measured total muscarinic receptor
density on non-failing and failing human heart samples, and determined if demonstrated
differences were reversed through mechanical unloading with a left ventricular assist
device (LVAD). Through radioligand binding assays, we found a significant increase in
receptor density in failing human heart samples compared to control (275.8 ± 11.9 versus
194.1 ± 17.3 fmol/mg protein; p<0.01), along with an increase in receptor density in
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failing with LVAD support samples(315.8 ± 23.9 versus 194.1 ± 17.3 fmol/mg protein;
p<0.001).
We also measured M1-M4 receptor subtypes on a subset of these samples. While the
percent of M1, M2, and M4 receptor subtypes did not significantly change between nonfailing, failing, and failing with LVAD support samples, the percent of M3 was
significantly decreased in failure (8.61 ± 1.65 versus 13.56 ± 2.16 %; p<0.05) and
increased back to non-failing percents in the failing + LVAD group (16.65 ± 0.72 versus
8.61 ± 1.65 % in failure; p<0.01).
Muscle function analysis was also performed. Acetylcholine and isoproterenol were
used to determine if a change in total muscarinic receptor density in groups related to a
change in functional response on fresh trabecular muscles; with and without SNS
stimulation. Recovery in contractile parameters without SNS stimulation on ACh-treated
muscles, and greater negative inotropic and chronotropic effects on ACh-treated muscles
with SNS stimulation provide evidence that total muscarinic receptor density changes
elicit different responses on the failing human heart.
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CHAPTER I
INTRODUCTION

Heart failure (HF) is a condition affecting approximately 5.8 million Americans every
year34. 670,000 new cases are diagnosed annually, and although there are treatment
options, 1 in 5 people die within 1 year of diagnosis34. Currently, implantable medical
devices and drug therapy are used in the management of HF, however the prevalence of
this syndrome continues to be overwhelmingly high. In the heart, rate and force of
contraction are regulated by the autonomic nervous system (ANS). Areas of the ANS
including the sympathetic nervous system (SNS) are altered in failure, which has led to
new drug therapy targets. The counterpart of the SNS, the parasympathetic nervous
system (PNS), is not as well understood in HF. With HF being one of the leading causes
of mortality, it is important to expand research for more successful treatment options.
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1.1 Human Heart Failure
Heart failure (HF) is a disorder characterized by an inability of the heart to pump
blood throughout the body40. The onset of HF is gradual, and it is the most common
diagnosis in patients over the age of 6540,18. This syndrome is heterogeneous, with
common symptoms such as breathlessness, fatigue, and fluid retention40.
Cardiomyopathy is one diagnosis that leads to HF59. There are different types of
cardiomyopathy, such as ischemic and dilated cardiomyopathy. As shown in Figure 1,
these arise when the heart is enlarged and ventricular walls become thin and weakened.
Ischemic cardiomyopathy occurs when the heart weakens due to coronary artery
disease36. Arteries block with plaque, causing the heart to have difficulty filling and
pumping blood to the body36. In dilated cardiomyopathy, the cause is often unknown36.
Dilated cardiomyopathy can affect any age group, and can be genetic or caused by
alcohol and drug abuse, stress, or a virus36.
Molecularly, HF arises when myocytes undergo remodeling, meaning they change in
size, shape, and function7. Remodeling is an effect of cardiomyocytes responding to
biomechanical stressors stimulating molecular and cellular events that lead to the
characteristic failing heart7,43. At first, these events are stimulated to compensate for the
failing heart. But after continual stimulation, they progressively exacerbate the disease
and worsen prognosis. These events are a complex series of interactions that mediate
various responses on the heart, including rate and force of contraction. Examples of
important changes seen in HF include alterations in calcium-cycling proteins and
autonomic nervous system regulation10,13,40.
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Non-Failing Heart

Failing Heart

Figure 1. Non-Failing versus Failing Human Heart.
Non-failing (NF) human hearts, about the size of a
clenched fist, are significantly smaller than severely failing
hearts. Notable features of the failing heart include
enlarged chambers and thinned ventricular walls. (Figure
modified from www.intensivecare.hsnet.nsw.gov.au)
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Alterations in Ca++ signaling contribute to depressed contractility seen in HF. Because
of the complexity of Ca++ regulation in healthy hearts, it is difficult to pinpoint exact
causes of reduced Ca++ transport in failure. One mechanism involves the sarcoplasmic
(endoplasmic) reticulum Ca++ ATPase protein SERCA. Studies have shown a reduction
in SERCA signaling in HF and improved contractility upon increased expression23,24.
The protein that interacts with SERCA to inhibit reuptake of Ca++, phospholamban
(PLB), is also a target of investigation. Research supports that decreased levels of PLB
play a role in decreased Ca++. Along with finding decreased levels of SERCA and PLB,
investigators have shown decreased expression of L-type Ca++ channels and ryanodine
receptors (RYRs), and increased expression of Na+-Ca++ exchanger (NCX)23.
The complexity of HF makes the condition difficult to treat. Heart transplantation is
the most effective form of treatment, yet only about 2,300 patients each year are able to
receive a transplant21. Drug therapy, surgery, and device therapy are currently the
mainstay in managing HF.

1.2 Left Ventricular Assist Devices (LVADs)
Left ventricular assist devices, or LVADs, are surgically-implanted pumps that run via
battery. They take over pumping ability in severely failing hearts when heart
transplantation is not presently available31. During LVAD support, hearts are
hemodynamically unloaded so they can continue to beat without having to perform work.
As shown in Figure 2, LVADs are implanted from the apex of the left ventricle to the
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Figure 2. Left Ventricular Assist Device. Although differing
models of LVADs are available, typical devices are implanted
from the apex of the left ventricle to the ascending aorta, with a
pump lying in the abdomen or thoracic cavity. These devices
take the workload off of the left ventricles by allowing blood to
flow through the left ventricle, while the device pumps the
blood out to the aorta. (Figure from www.heartfailure.org)
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ascending aorta. Blood is pumped from the lungs to the left atrium and into the left
ventricle. Blood is pulled from the left ventricle and into the device. The device pumps
blood into the aorta to be sent systemically through the body. The pump’s battery and
control system are kept outside the body, and are connected through a drive line to the
pump inside the body.
LVADs were first used as a bridge-to-transplant therapy for patients on the cardiac
transplantation list. However, research in the past decade has shown LVADs to increase
survival rates and prognosis, leading to implantation of these devices as destination
therapy20,48.
Rose et al found that patients with LVAD support survived a median 408 days while
patients without a device survived a median 108 days48. Physical ability exams and
quality of life questionnaires were also examined from the same patient population,
resulting in significantly higher physical function and qualities of life in patients with
LVAD support.
At the myocyte level, there is evidence that LVADs reverse remodeling of the failing
heart. In failing hearts treated with LVADs, contractile function of myocytes
recovered20. Contractile functions restored included the magnitude of shortening, and
developed tension and relaxation rates20,42. LVAD support also was found to improve
neurohormonal systems, calcium handling, cytoskeletal protein abundance, and metabolic
signaling12,14,20,28,53. Beta-adrenergic receptor signaling, a component of the ANS, was
also restored upon LVAD support42.
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1.3 Autonomic Nervous System
The ANS regulates functions of the body, including airflow, body temperature,
digestion, blood pressure, and heart rate49. It is often referred to as a ‘self-governing’
system and controls processes that are responsible for maintaining homeostasis49. There
are two major divisions of the ANS: the sympathetic (SNS) and parasympathetic (PNS)
nervous systems. These two systems innervate the same target organs, and either
cooperate or contrast with one another to produce different effects on the body49. The
SNS and PNS are not opposites; rather, they form a web of complex interactions
responsible for maintaining proper balance between the two systems44. The SNS and
PNS can, depending on the target organ, be either stimulatory or inhibitory and act
simultaneously to produce an effect49.
The SNS is often referred to as the ‘fight or flight’ division of the ANS. It adapts the
body for more physically active situations, and is usually employed in states of arousal,
anger, danger, fear, etc49. In the heart, stimulation of the SNS causes an increase in heart
rate and force of contraction.
The PNS is often referred to as the ‘rest or digest’ division of the ANS. It is used
predominantly in non-physically active situations such as in the process of digestion. In
the heart, stimulation of the PNS causes a decrease in heart rate and force of contraction
and is of stronger influence than the SNS at rest. PNS signals to the heart travel through
the vagus nerve, one of the cranial nerves. The brain receives signals from sensory
receptors about conditions of the heart such as heart rate before signals are sent to carry
out necessary responses. In the PNS, long preganglionic nerve fibers carry the signal
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from the brain and synapse with short postganglionic nerves. At the synapse,
acetylcholine is released and binds to nicotinic receptors on postganglionic fibers. The
signal travels through these fibers and reaches the target organ. Here, acetylcholine is
released again, this time binding to muscarinic receptors on cardiomyocytes49.

1.4 Autonomic Nervous System and Heart Failure
An imbalance of the ANS is a defined characteristic in the progression of HF1.
Because of this, it is important to be able to evaluate autonomic activity in cardiovascular
disease. Research concludes that increase in SNS activity and decrease in PNS activity
are related to an increased risk of death in cardiovascular disease29. However, it is
difficult to quantify ANS activity because of its complexity29. Therefore, exploring
various markers that reflect autonomic activity remains a vital area of research.
The SNS increases heart rate and force of contraction in a non-diseased state. It is
activated when norepinephrine (NE) binds to beta-adrenergic receptors (β-AR) on
cardiomyocyte plasma membranes (signaling pathway depicted in Figure 3). These βARs interact with heterotrimeric Gs proteins that stimulate adenylyl cyclase. This
effector molecule dissociates ATP into cyclic-AMP to bind protein kinase A (PKA).
PKA phosphorylates L-type Ca++ channels, RYRs, PLB, and troponin I, which causes an
increase of Ca++ movement. Increase in Ca++ ultimately causes a positive inotropic and
chronotropic effect on the heart.
In HF, the SNS is overactivated. This system first acts to compensate for declining
cardiac function, yet long-term activation decompensates cardiac function55. A notable
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Figure 3. β-AR Signaling Pathway. Agonists, such as norepinephrine bind
to β-ARs on cardiac myocytes which stimulates Gs proteins to active
adenylyl cyclase (AC). Through downstream signaling, proteins that
increase Ca++ movement within the cell are activated by phosphorylation.
An increase in Ca++ movement results in a positive inotropic and
chronotropic effect.
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and well-studied feature of the SNS in HF is alterations in β-AR density. It has been
found that β-AR density is significantly downregulated in the failing heart4,13,55.
Specifically, the ratio of β-AR subtypes, β1 and β2, drop from approximately 75:25 in a
non-diseased state to 60:40 during failure4. β1-AR population decreases while β2 does
not significantly change4. β-AR downregulation is the result of high concentrations of
NE leading to desensitization of the receptor. What has been developed with the 20+
years of research on β-ARs are drug therapies targeting and blocking these SNS receptors
from activating signaling pathways. These drugs, commonly called β-blockers, are now
universally used to decrease sympathetic overactivation in the failing heart. In studying
LVAD support and the SNS, β-AR density has been shown to be restored through LVAD
support with densities closely mimicking non-failing results42.
The role of the PNS in HF is not as clear. It is established that autonomic dysfunction
in HF is related to overactivation of the SNS and attenuation of the PNS. To examine
PNS control, vagal nerve studies have been an area of recent research. Stimulation of the
vagus nerve has improved cardiac function and increased survival in various models of
HF33,51,54,61. This occurs primarily because acetylcholine released from the vagus
interacts with cholinergic receptors on cardiomyocytes and inflammatory cells54. PNS
regulation of heart rate is increased, along with inhibiting release of inflammatory
cytokines such as tumor necrosis factor (TNF) and interleukin-1 (IL-1)54. With these
changes upon vagal stimulation, autonomic balance improves and inflammatory
responses are supressed61. Vagal nerve stimulation is shown to be of potential
therapeutic benefit and is one way of targeting the PNS in HF.
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Because SNS activity was studied using the target membrane receptor on
cardiomyocytes, another way to examine PNS activity is to study the target receptor of
the PNS: muscarinic receptors. Up to this point, attempts to study the PNS in HF this
way have led to conflicting results, thereby no definitive conclusions have been drawn
1,3,19,32,56

.

1.5 Muscarinic Receptors
Muscarinic receptors belong to the family of receptors known as g-protein coupled
receptors (GPCRs). GPCRs are one of the most abundant and diverse of protein families,
and the most common type of cardiac receptor27,47. There are an estimated six major
classes of GPCRs, which are thought to be of early evolutionary origin due to their
presence in bacteria and yeast27. The ANS utilizes adrenergic and muscarinic cholinergic
receptors to maintain homeostasis in the heart and cardiovascular system47. Muscarinic
receptors are expressed in a variety of cells and are further broken down into five specific
subtypes5,16. These subtypes are named M1-M5, based on the order of their discovery16.
Muscarinic receptors are composed of seven transmembrane alpha helices, with an
extracellular N-terminus and intracellular C-terminus27. These seven hydrophobic
transmembrane domains are connected by three extracellular and three intracellular
hydrophilic loops16. M1-M5 share 90% of their amino acid sequences within their
hydrophobic domains and differ the greatest in their loop and tail regions16. In the heart,
M2 is thought to be the most predominant, and at one time, was thought to be the only
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subtype present on cardiomyocytes5,8,45. More recent studies, however, have suggested
multiple subtypes existing in mammalian heart tissue52,58.
Muscarinic receptor subtypes differ in signaling pathways. All GPCRs rely on an
extracellular stimulus to activate intracellular signals via interaction of heterotrimeric G
proteins with the receptors’ intracellular loops27. In basic signal transduction, a ligand
binds to its appropriate receptor to stimulate a conformational change of the receptor.
This change in conformation leads to activation of an associated heterotrimeric G protein,
allowing for the G protein’s α subunit to dissociate from its β and γ subunits. The G
protein subunits activate and amplify signals within the cell by altering activity of an
effector molecule. The activities of the effectors control production of second messenger
molecules leading to a variety of downstream signaling pathway activation16,27,47.
Although all muscarinic receptors use this basic signal transduction mechanism, the
subtypes differ in G proteins, effectors, and second messengers, leading to different
cellular responses. The even-numbered muscarinic receptor subtypes, M2 and M4, couple
to a Gi protein, while M1, M3, and M5 interact with a Gq protein. For all five subtypes,
initial conformational change occurs when acetylcholine binds to the receptor. Illustrated
in Figure 4, M2 and M4, upon activation of Gi, inhibit adenylyl cyclase (AC) activity,
leading to a reduction in intracellular levels of cAMP16. This inhibits cyclic AMPdependent kinases (PKA) from phosphorylating proteins such as L-type Ca++ channel,
RYRs, PLB, and troponin I, causing a decrease in movement of Ca++. This pathway
antagonizes the SNS signaling pathway and is active after stimulation of the SNS. Evennumbered muscarinic receptors also directly open K+ channels on the plasma membrane,
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Figure 4. Even-Numbered (M2/M4) Muscarinic Receptor Signaling Pathway.
Agonists, such as acetylcholine (ACh), bind to muscarinic receptors on cardiac
myocytes which activate Gi proteins. Gi proteins antagonize the β-AR signaling
pathway by inhibiting AC from increasing intracellular cAMP levels. This results
in a decrease in Ca++ movement within the cell which produces a negative
inotropic and chronotropic effect on the heart.
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turning off the electrical signals caused by depolarization, reducing contractility, however
evidence in ventricular tissue is lacking25. M1, M3, and M5, upon activation of Gq,
activate phospholipase C (PLC) (signaling pathway depicted in Figure 5). PLC
hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate
(IP3) and diacylglycerol (DAG)5,16. DAG stimulates protein kinase C (PKC) while IP3
releases Ca++ from the SR, leading to an increase in heart rate and force of contraction25.
Because the M2 receptor subtype is thought to exert greater influence than the other
subtypes on cardiomyocytes, the predominant effect of muscarinic stimulation to the
heart is inhibitory.

1.6 Research Goal
The goal of this project is to study the role of the PNS in human HF. The hypothesis
that the PNS is dysregulated in human HF will be tested using muscarinic receptor
density as a measurable variant of PNS activity. Total muscarinic receptor densities will
be measured using a modified radioligand binding assay protocol, while muscarinic
subtypes will be measured using a time-dependent competition binding assay. With these
established techniques, muscarinic receptor densities in non-failing and failing human
heart samples will be analyzed. Muscarinic receptor densities in failing tissue samples
from patients who had LVAD support will also be studied. This population will allow us
to explore the restoring capabilities of LVADs on the PNS. Once densities in nonfailing,
failing, and failing + LVAD support heart tissue samples are measured, muscle function
analyses will be performed. Muscle function experiments will provide insight on the
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Figure 5. Odd-Numbered (M1/M3/M5) Muscarinic Receptor Signaling Pathway.
Agonists, such as acetylcholine, bind to odd-numbered muscarinic receptors on
cardiac myocytes which stimulate Gq proteins. Gq proteins activate phospholipase
C (PLC) which hydrolyzes PIP2 into IP3 and DAG. DAG activates a downstream
pathway by PKC while IP3 directly activates Ca++-channels on the SR, leading to
an increase in Ca++ release. This increase in Ca++ results in a positive inotropic and
chronotropic effect. (Abbreviations: PIP2 = phosphatidylinositol 4,5bisphosphate; IP3 = inositol 1,4,5-triphosphate; DAG = diacylglycerol; PKC =
protein kinase C; SR = sarcoplasmic reticulum)
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inotropic response of fresh trabecular muscle upon acetylcholine and isoproterenol
stimulation. Results from these experiments will be used to compare contractility
changes to receptor density changes in each population. Conclusions found through the
data analysis may provide for a novel approach in tackling human heart failure, leading to
better and more effective treatment options.
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CHAPTER II
METHODS

2.1 Human Hearts
Human hearts were obtained from a patient population only after IRB approval and
patient consent. Left ventricular (LV) tissue was obtained from patients with non-failing
hearts, failing hearts, and failing hearts which had been supported by an LVAD prior to
transplant. Non-failing and failing samples were used to compare the effects of heart
failure on muscarinic receptor density. In anticipation of finding differences, a second
failing group was studied to explore the recovery of muscarinic receptors by mechanical
unloading in patients with an LVAD (failing + LVAD). Non-failing hearts were obtained
from unmatched organ donors whose hearts were unsuitable for transplantation. Failing
and failing + LVAD groups were the explanted hearts of cardiac transplant recipients at
Cleveland Clinic. Inclusion criteria for donor sample selection were males and females,
between 40-65 years of age. Since left ventricular ejection fractions above 50%
demonstrate normal cardiac function, only donor hearts with ejection fractions ≥ 50%
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were included. Inclusion criteria for failing and failing + LVAD samples were males and
females, between 40-65 years of age, with an ejection fraction <35%. Exclusion criteria
included pacemakers because of the unknown effect pacing may have on autonomic
nervous system regulation. Samples were also excluded if patients were on drugs with
potential muscarinic interactions. These included sotalol, amiodarone (for non-failing
and failing samples only), disopyramide, quinidine, and atropine. These drugs were
excluded based on previously reported drug/receptor interactions9,11,38,39,41. Right atrial
tissue was also obtained from heart failure patients undergoing cardiac transplantation
and a piece of de-identified brain tissue was acquired from the Department of Pathology
at CC. Both served as positive controls.
For muscle function analyses, fresh trabecular muscles were taken from non-failing
and failing patients immediately following acquirement of tissue from operating rooms.
Non-failing left ventricular tissue came from patients with hypertrophic cardiomyopathy
(HOCM) and failing left ventricular tissue came from explanted hearts of cardiac
transplant recipients at Cleveland Clinic. Non-failing tissue included both males and
females, aged between 41-74 years, and with ejection fractions >50%. Failing tissue
included both males and females, between 46-68 years of age, with ejection fractions
below 35%.
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2.2 Membrane Preparation
Frozen human heart samples were broken into pieces weighing 2.0-2.2 g and placed
into Buffer A [composition: 10mM (4-(2-hydroxyethyl)-1-Piperazineethanesulfonic acid
(HEPES), 5mM Ethylene glycol tetraacetic acid (EGTA), 12.5mM Magnesium Chloride
(MgCl2), 250mM Sucrose, 10mg/mL Leupeptin, 20µg/mL
Phenylmethanesulfonylfluoride (PMSF), 20µg/mL Bacitracin, 20µg/mL Benzamidine].
Samples were homogenized in 3 second bursts with 5 second rests on ice until no chunks
of tissue remained. Homogenates were centrifuged at 300 x g for 5 minutes at 4ºC to
pellet out heavier organelles such as nuclei and mitochondria. Supernatants (containing
lighter cytosolic fragments such as actin/myosin filaments and membrane fragments)
were incubated in 0.5M KCl solution for 15 minutes at 4ºC to destroy the myofilaments
in the supernatant. Suspensions were centrifuged at 40,000 x g for 15 minutes at 4ºC to
pellet the membrane fraction. The supernatant was discarded and pellets were added to
buffer B, a non-sucrose containing buffer [composition: 20mM HEPES, 5mM EGTA,
12.5mM MgCl2, 100mM NaCl; and 20µg/mL each of Leupeptin, PMSF, Bacitracin, and
Benzamidine)]. In buffer B, pellets were Dounce homogenized (10 times slowly with a
loose plunger followed by 10 times slowly with a tight plunger) to refine the membrane
fraction. Once each sample was homogenized, preparations were centrifuged to re-pellet
membrane preparations (40,000 x g for 15 minutes at 4ºC). Pellets underwent a second
series of homogenization to further refine the membranes. Preparations were centrifuged
at 40,000 x g for 15 minutes at 4ºC. Final pellets were added to buffer B + 10% glycerol
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to help preserve the membranes upon storage. Pellets were resuspended using a
motorized homogenizer until they were fully suspended. Aliquots were stored at -80ºC.

2.3 Determination of Protein Concentration
Lowry protein assays were performed on membrane preparations to determine total
protein concentrations. Standards containing known concentrations (0.0, 0.5, 1.0, 2.0,
3.0, 4.0 mg/mL) of bovine serum albumin (BSA) were added to a 96 well plate, in
triplicate. 1:2 dilutions of membrane preparations were also added in triplicate to the 96
well plates. Reagent A, a solution that recognizes peptide bonds and binds to all protein,
was added to each standard and sample. Reagent B, a solution that recognizes reagent A
and, upon binding, produces a color change, was then added to each well. The standards
and samples were incubated for 15 minutes at room temperature. The absorbance was
read at 750nm. The known concentrations of BSA were used to generate a standard
concentration curve from each standard’s measured absorbance and this was then used to
determine the unknown sample concentrations.

2.4 Membrane Titer Assay
A radioligand binding assay was used to measure total muscarinic receptor density and
affinity. Before beginning these experiments, the amount of membrane necessary to
attain 10% specific binding was determined using a membrane titer assay.
In a membrane titer assay, a non-selective radiolabeled antagonist (3H-Quinuclidinyl
benzilate) is added to membrane to determine total binding to muscarinic receptors. Non-
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specific binding is determined by adding 3H-QNB in the presence of a second nonselective and non-labeled muscarinic receptor antagonist (atropine). Atropine is added in
a high concentration in order to ensure atropine binding to the muscarinic receptor, such
that any radioactivity remaining is due to 3H-QNB binding to something other than
receptor. By subtracting non-specific binding from total binding, specific binding can
then be determined. 3H-QNB is also measured in the absence of membrane to ascertain
total counts of radioactivity. Final calculations are performed to determine the amount of
membrane needed for specific binding to equal 10% of total counts of radioactivity.
Details for this assay are as listed below.
All steps prior to incubation were performed on ice. Six 12x75mm polypropylene
tubes were used for each heart sample: three to measure total binding in triplicate and
three to measure non-specific binding, also in triplicate. A buffer containing 20mM
HEPES, 15mM EGTA, 1.25mM MgCl2 (HEM) and 0.1% BSA was added to all total
binding and non-specific binding tubes and was used to prepare 3H-QNB, atropine, and
membrane.
For this assay a theoretical Kd taken from the literature was used58. 250pM of 3HQNB was added to all total binding, non-specific binding, and total count tubes.
Atropine (non-selective, non-labeled) was added to the non-specific binding tubes to
achieve a 1µM antagonist concentration.
Membrane preparations were added last. Frozen aliquots of tissue samples were
thawed on ice and diluted to 25µg protein per tube. Preparations were added to total and
non-specific binding tubes.
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Tubes (with a final volume of 250µL) were mixed on a Vortex mixer and placed in a
shaking water bath for 1 hour at 37ºC. After incubation, preparations were harvested
onto GF/C filter paper, and washed five times with cold HEM. Filters were cut out and
placed in 7mL scintillation vials and set in a 42ºC oven to dry. Once dried, 5mL of
Cytoscint ES scintillation fluid was added to each vial. Vials were capped, mixed, and
then wiped with a dryer sheet (to avoid artificially high values due to static discharge).
Vials were read in a scintillation counter for two minutes each.

2.5 Measuring Total Muscarinic Receptor Density and Affinity
A radioligand binding assay was used to measure total muscarinic receptor density and
Kd. In this assay, multiple doses of 3H-QNB were added to samples to generate a
saturation curve and Lineweaver-Burk plot.
Forty-eight 12x75mm polypropylene tubes were used per heart. For each heart, three
tubes were used to measure total binding and three were used to measure non-specific
binding (run in triplicate) at each dose of radioactivity. Eight doses of radioactivity were
utilized in this assay.
Eight differing doses of 3H-QNB were made. The highest dose (1500pM) of
radioactivity was prepared and the seven other doses were serial diluted from the highest
dose to achieve final concentrations [concentrations in pM: 11, 27, 68, 135, 270, 540,
900, 1500]. Buffer and atropine were added as described in Section 2.4.
Membrane preparations were added last. Frozen aliquots of tissue samples were
thawed on ice and diluted to amounts determined by the membrane titer assay.
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Tubes were mixed and placed in a shaking water bath for 1 hour at 37ºC. After 1
hour, preparations were harvested onto GF/C filter paper, dried, and read as described in
Section 2.4.
Results generated a saturation curve measuring concentration of radioactivity to
amount of binding. A Lineweaver-Burk plot was created by plotting binding (pmol/mg)
to the ratio of bound vs. free radioactivity. The x-intercept of this plot was equivalent to
the Bmax (density) of the sample and the slope equals the Kd. An example of a
saturation curve and Lineweaver-Burk plot is depicted in Figure 6.

2.6 Measuring Muscarinic Receptor Subtypes
Muscarinic receptor subtypes were measured using a time-equilibrium binding assay.
In this assay, one concentration of radioactivity was used and changes in binding were
measured over a two hour time course in the presence of the selective non-labeled
antagonist for each subtype. Saturation curves were generated to determine the fraction
of each subtype. An example is shown in Figure 7.
One hundred and eighty 12x75mm polypropylene tubes were used per heart. Thirty
tubes were used for each condition (total binding, nonspecific binding, antagonist binding
for M1, M2, M3, and M4). Buffer and atropine was added as described in Section 2.4.
After preliminary studies and a literature search, Ki’s were determined for the project.
To measure subtypes, non-labeled subtype-selective antagonists were used [in 1mM: M1
– Pirenzepine, M2 – Methoctramine, M3 – p-Fluoro-hexahydrosila-difenidol (pf-HHSiD),
M4 – Tropicamide]. No current subtype selective antagonist is available for M5 and this
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Figure 6. Saturation Curve (Top) and Lineweaver-Burk Plot (Bottom).
Radioligand binding assays generate a saturation curve and Lineweave-Burk plot
to determine density and Kd of samples. The Lineweaver-Burk plot is a linear
interpretation where specific binding is plotted against the ratio of bound to free
radioactivity. The x-intercept of a Lineweaver-Burk plot is the Bmax, or density
of the receptor of interest. The Kd is interpreted by the slope of the line.
(Abbreviations: B = Specific Binding, B/F = Specific Binding divided by the
Concentration of Free Radioligand)
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Figure 7. Saturation Curve for the Time-Dependent Competition Binding
Assay. Percent binding of muscarinic subtypes were found by generating
best-fit lines (shown on the right) from saturation curves (shown on the left).
The values at the 2 hour time-point were fractioned from specific binding to
determine results.
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receptor subtype was therefore not measured in this study. Each antagonist was added at
its established Ki value. Ki values were as follows (in M): Pirenzepine = 4.66 x 10-9,
Methoctramine = 6.18 x 10-8 pf-HHSiD = 1.92 x 10-8, Tropicamide = 2.82 x 10-8.
Holding radioactivity at 150pM per tube for all total binding, non-specific binding,
and total count tubes, membrane (amount determined from membrane titer assay) was
incubated in the presence of the selective antagonists. Tubes were mixed. Incubations
were run in a shaking water bath at 37ºC. Tubes were incubated at ten different time
points (in minutes: 0, 10, 20, 30, 45, 60, 75, 90, 105, 120). Once complete, incubations
were halted by placing tubes back into an ice water bath. Preparations were harvested,
dried, and read as described in Section 2.4.

2.7 Muscle Function Experiments
Fresh trabecular muscles from non-failing, failing, and failing + LVAD tissues were
used in this experiment. Tissue samples were collected from the operating room and
placed in cold cardioplegia solution. Once in the lab, tissue samples were placed in an
oxygenated petri dish filled with Krebs-Henseleit buffer (KHR) [composition in nM: 100
NaCl, 4.0 KCl, 1.5 MgSO4*7H2O, 20.0 NaHCO3, 1.5 NaH2PO4, 20.0 Na-Acetate, 10.0
Glucose, 0.1 Ascorbic Acid, 2.5 CaCl2, and 5.0 IU Insulin]. Up to 7 long, slender
cylindrical muscles with a cross sectional area less than 1.1 mm2 were dissected from the
tissue. Each muscle was secured between two o-rings and transferred to the muscle
experiment set-up.
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A typical muscle experiment set-up is depicted in Figure 8. Each muscle is
surrounded by a tissue bath filled with oxygenated KHR continuously heated at 37ºC.
Inside the bath, muscles are hung by two hooks and are in direct contact with platinum
electrodes. These platinum wires send electrical stimuli (1Hz every 5msec) to the muscle
via a stimulator. The stimulator controls the frequency, duration, and amount of voltage
of each stimulus sent to the muscle. After the muscle is stimulated, the muscle produces
tension in response to the stimulus, which is sensed by a force transducer. This sends the
amount of force generated by the muscle to an amplifier which amplifies and conditions
the signal and sends it to LabChart 7 Pro, a software program. Once on data acquisition
software, results can be analyzed for six different contractile parameters. Contractile
parameters analyzed are shown in Figure 9. These parameters include resting tension
(RT), developed tension (DT), time to peak tension (TPT), time to half relaxation (THR),
peak rate of tension rise (+dT/dt), and peak rate of tension fall (-dT/dt). RT is the tension
produced by the muscle at rest and DT is the force produced by the muscle during
contraction. TPT is the time it takes for the muscle to reach its peak of contraction and
THR is the time it takes for the muscle to get from the peak of contraction to the halfway
point of relaxation. dT/dt is the maximal rate of contraction (+dT/dt) or relaxation (dT/dt).
Once hung on the set-up, each muscle remained in the bath for one hour without
electrical stimulation. Muscles were then stimulated repeatedly for two minutes at 10V
to reach a steady state of contraction. The threshold voltage was found by lowering
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Trabecular
muscle

Tissue bath with Krebs-Henseleit

buffer maintained at 37°C
Figure 8. Typical muscle bath set-up. Each dissected muscle is secured
between two o-rings and hung across a pair of platinum electrodes.
Muscle baths are then lifted to surround the muscle with circulating,
oxygenated Krebs-Henseleit buffer heated to 37ºC.
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Tension (g)

THR
DT

RT
TPT

Time (sec)
Figure 9. Typical muscle contraction with contractile parameters.
From an individual muscle contraction, determination of six
contractile parameters are used to establish functionality, including
resting tension (RT), developed tension (DT), time to peak tension
(TPT), and time to half relaxation (THR). Peak rate of tension rise
(+dT/dt) and peak rate of tension fall (-dT/dt) (not shown) are
established at the steepest slope of the line leading to the peak of
contraction and the steepest slope of the line leading back to RT.
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voltage to 1V and increasing by 0.2V until the muscle began contracting. Upon
contraction, voltage was increased by 20% which set the voltage for the remainder of the
experiment.
A length-tension curve (LTC) was performed once muscles were contracting steadily
at threshold voltage. Muscles were stretched by 0.1 mm. After one minute at the new
length, DT and RT were recorded. These steps were repeated until DT stopped
increasing upon stretch of the muscle to reach Lmax (length associated with greatest
muscle contraction). Setting each muscle to its Lmax allowed for individual muscles to
be compared to others. Once each reached Lmax, muscles were left for 30 minutes to
stabilize under these new conditions. After 30 minutes, muscles with DT ≥ 0.20g were
used for the experimental protocol.
Muscles were divided into two groups: those that received Acetylcholine (Ach) and
those that served as time controls. A dose-response curve to Ach was performed. 1nM
Ach was added only to the experiment group of muscles. After ten minutes, 10nM Ach
was added. This series was repeated until six doses of Ach was added (1, 10, and
100nM, followed by 1, 10, and 100µM). After the last dose was added followed by the
10 minute rest, all muscles received 1µM isoproterenol.
Once the experimental protocol was complete, muscles were removed from KHR so
the length between their o-rings could be measured. Once recorded, muscles were cut
from the o-rings and placed in bibulous paper to dry. After drying for 15 minutes,
individual muscles were weighed, so cross-sectional area (XSA) could be calculated.
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XSA = (weight of muscle / length of muscle) ÷ density of muscle. RT, DT, +dT/dt, and –
dT/dt were divided by XSA to normalize for muscle size.
Data recorded throughout the experiment was analyzed in order to draw conclusions.

2.8 Statistical Analysis
Total muscarinic receptor density and the percent of muscarinic receptor subtypes in
non-failing, failing, and failing+LVAD tissue were analyzed using a one-way analysis of
variance (ANOVA) and a Newman-Keuls post-hoc comparison test. Diagnoses (dilated
cardiomyopathy versus ischemic cardiomyopathy) in failing and failing+LVAD groups
were analyzed by a Kruskal-Wallis test followed by the Dunn’s Multiple Comparison
test. The Kruskal-Wallis test and Dunn’s Multiple Comparison test was also used to
determine total muscarinic receptor Kd changes between groups. Data is expressed as
mean ± SEM and significant differences were determined only when p < 0.05.
Baseline parameters in the muscle function experiments were analyzed using an
unpaired t-test if the parameter passed a normality test or a Mann Whitney test if the
parameter did not pass a normality test. Dose-response curves were analyzed by a twoway ANOVA followed by the Bonferroni post-test. A two-way ANOVA and Bonferroni
post-test was also used to determine the response of muscles upon the addition of
isoproterenol. Data is expressed as the mean ± SEM for baseline parameters, mean
percent change from baseline for dose-response curves, and mean percent change from
the last dose of acetylcholine for isoproterenol data. Significant differences were
determined only when p < 0.05.
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CHAPTER III
RESULTS

3.1 Total Muscarinic Receptor Density and Affinity
Table I shows the patient population used to measure muscarinic receptors (all = total;
highlighted in grey = subtypes; Table I on page 32, description of Table I on page 33).
Patients of both sexes were included in the study and sample groups were chosen to have
a similar age (in mean ± SD; NF = 49 ± 5, F = 51 ± 5, and F+LVAD = 52 ± 8). Because
ejection fractions ≥ 50% are a marker of normal cardiac function, NF samples only with
ejection fractions ≥ 50% were included. F and F+LVAD samples had ejection fractions ≤
50%. Exclusion criteria was also considered, therefore patients on pacemakers or on
drugs with potential muscarinic interactions were excluded from the study. Common
medications taken by the patient population are included in Table I, with patients most
commonly on β-blockers, angiotensin converting enzyme (ACE) inhibitors, and
inotropes. Sixty-one total left ventricular samples were used to measure total muscarinic
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Patient #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61

Diagnosis
NF
NF
NF
NF
NF
NF
NF
NF
NF
NF
NF
NF
NF
NF
NF
F-DCM
F-DCM
F-DCM
F-DCM
F-DCM
F-DCM
F-DCM
F-DCM
F-DCM
F-DCM
F-DCM
F-DCM
F-DCM
F-DCM
F-DCM
F-ICM
F-ICM
F-ICM
F-ICM
F-ICM
F-ICM
F-ICM
F-ICM
F-ICM
F-ICM
F-ICM
F-ICM
F-ICM
F-ICM
F-ICM
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD
F+LVAD

Age
60
54
42
53
44
50
44
50
50
48
55
46
56
47
40
40
48
54
56
47
45
49
53
46
53
41
50
52
45
52
56
60
52
58
53
52
56
43
53
55
48
54
58
58
55
42
50
43
59
54
53
51
44
43
39
62
62
54
65
65
49

Sex
F
F
M
F
M
M
F
M
F
F
F
F
F
F
M
M
F
M
F
M
M
F
F
M
F
M
M
F
F
M
F
F
M
M
M
M
M
F
M
F
M
F
F
M
F
M
M
M
M
M
F
M
M
M
M
M
F
M
M
M
M

Ejection Fraction
65
N/A
N/A
50
75-80
60
55-60
70
65-70
50-55
60
70
65
50
60
10
15
15
25
30
10
30
15
15
20
10
10
10
15
25
15
25
24
15
35
15
15
30
15
15-20
20
10
35
20
20
15
10
15
10
15
10
15
10
N/A
10
50
15
20
25
20
10
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Medications
DOB, NE
NE
DOP
DOP, EN
DOP
DOB
DOP, NE
N/A
DOP, NE
DOP
DOP
NE
DOP, EN
DOP
DOP
NE
CARV, DIG, LIS
LOS
CARV, LIS, MIL
LIS, MET
LIS, MIL
N/A
CARV, DIG, DOB, DOP, MIL, NE
CARV
CARV, MIL
CARV
DOP
CARV, DIG
CARV
DIG, LIS, M ET
LIS, MET
CARV
CARV
MET, MIL
CARV, DIG, VAL
DIG, MIL
CARV, MIL
CARV, MIS
MIL
CARV
LIS
DIG
N/A
CARV
DIG
EN
N/A
DIG
N/A
DOB, DOP, EPI, NE
N/A
DOB
DOB
MET
CARV, DIG, DOP
DIG
N/A
CARV, LIS
N/A
CARV, LIS
LIS, MET

Table I. Characteristics of Patients Used to Measure Total and
Subtyped Muscarinic Receptors. Sixty-one human left
ventricular samples were used to measure total muscarinic
receptor density and 36 of these samples (highlighted in grey)
were also used to measure the percent of M1-M4 receptor
subtypes. Patients in each diagnosis were chosen with similar
ages and both males and females were used in the study. Ejection
fractions in NF tissue needed to be ≥ 50% and in F and F+LVAD
tissue ≤ 35% to be included in the study. Common medications
are also listed. (Abbreviations: DOB = Dobutamine, NE =
Norepinephrine, DOP = Dopamine, EN = Enalapril, CARV =
Carvedilol, DIG = Digoxin, LIS = Lisinopril, LOS = Losartan,
MIL = Milrinone, MET = Metoprolol, EPI = Epinephrine, VAL =
Valsartan)

34

receptor density and 36 of these samples were also used to measure the percents of
muscarinic receptor subtypes.
Before measuring total muscarinic receptor density on all 61 left ventricular samples,
positive controls were measured to ensure valid experimental technique. It is established
that there are a more dense population of muscarinic receptors in atrial tissue compared to
ventricular tissue and there are even greater densities in the brain than in the atria or
ventricles22,44. Using my established radioligand binding assay protocol, I measured
receptor densities on left ventricular and right atrial tissue (n=3 per group) from the same
hearts and from one piece of un-identified brain tissue. Figure 10 shows that the lowest
muscarinic receptor density was measured in the three left ventricular samples (332.70 ±
35.90 fmol/mg). The three hearts had a higher density in the right atrium, with densities
of 571.70 ± 93.78 fmol/mg. The brain tissue had receptor densities of 1029 fmol/mg
protein. The positive controls mimicking data in the literature supported the
experimental protocol we established, therefore the 61 project samples could be
successfully measured.
Figure 11 shows the results of the radioligand binding assays on the 61 project
samples. The 15 NF samples were found to have receptor densities of 194.10 ± 17.27, F
samples 275.80 ± 11.89, and F+LVAD samples 315.80 ± 23.94 (all in fmol/mg protein).
The F group was found to be significantly increased compared to control group (p<0.01)
and F+LVAD group was even more significantly increased compared to control
(p<0.001). Because the F and F+LVAD groups contained samples with a diagnosis of
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Figure 10. Positive Control Experiment. Right atrial and left
ventricular (LV) tissue was taken from the same 3 hearts (from
patients undergoing cardiac transplantation) and one piece of
un-identified brain tissue was acquired from pathology to
measure total muscarinic receptor densities.
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Figure 11. Total Muscarinic Receptor Density. A 1-way
ANOVA detected a significant increase in total muscarinic
receptor density in F samples compared to control (p<0.01) and
an even more significant increase in receptor density in
F+LVAD samples versus control (p<0.001).
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Figure 12. Relationship of Muscarinic Receptor Densities to Patient
Diagnosis. Total muscarinic receptor density comparisons were made
between DCM and ICM diagnoses in F patients and patients with
LVAD support. A statistical analysis was performed and found no
significant differences in density between etiologies (p=0.698). LDCM and L-ICM densities were also unchanged between groups
(p=0.974). (Abbreviations: DCM = Dilated Cardiomyopathy; ICM =
Ischemic Cardiomyopathy; L = F+LVAD group)
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both DCM and ICM, I wanted to see if various diagnoses of HF resulted in different
muscarinic receptor densities. As shown in Figure 12, when separating the F group into
F-DCM and F-ICM, receptor densities were unchanged (263.90 ± 20.98 versus 274.40 ±
16.80). Densities were also not significantly different when the F+LVAD group was
separated into diagnoses (316.70 ± 38.03 versus 315.00 ± 32.66). Groups were further
divided into male versus female to see if gender had an effect on muscarinic receptor
densities (F+LVAD group was not analyzed this way due to the uneven distribution of
males and females). A t-test was run to compare males to females in the NF group and
males to females in the F group, as shown in Figure 13. No significant differences were
found in the NF group, with females (n=10) having densities of 180.3 ± 17.9 fmol/mg
protein and males (n=5) with densities of 221.9 ± 37.4 fmol/mg protein. The F group
also showed no significant changes in receptor densities, with the mean density in
females (n=13) 289.9 ± 18.8 fmol/mg and males (n=16) 252.6 ± 17.7 fmol/mg protein.
LVADs, although all implantable pumps that hemodynamically unload the heart, have
developed into different types and are implanted for varying amounts of time from
patient to patient. Because of these factors, the type of LVAD was compared to see if
muscarinic receptor densities changed from LVAD type. Figure 14 compares muscarinic
receptor densities in different LVAD types. A Mann-Whitney analysis was performed
and found no significant changes in receptor density between pulsatile (284.5 ± 33.1
fmol/mg) and non-pulsatile (334.5 ± 32.6 fmol/mg) LVADs. Figure 15 compares the
duration of time patients were supported with an LVAD to their found muscarinic
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Figure 13. Gender Comparisons Between NF and F
Muscarinic Receptor Densities. NF and F muscarinic receptor
densities were separated into male (M) and female (F) groups to
see if differences in muscarinic receptor densities occurred with
gender differences. No significant changes in densities were
detected by t-test analysis for the NF (p=0.271) and F (p=0.162)
groups.
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Figure 14. Total Muscarinic Receptor Densities in
Different LVAD Types. Two types of LVADs, pulsatile
and non-pulsatile, were found to have no significant effect
on muscarinic receptor densities through a Mann-Whitney
statistical analysis (p=0.368).
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Figure 15. Relationship between duration of LVAD Support
and Total Muscarinic Receptor Density. The amount of time
patients were on LVAD support was compared to their found
muscarinic receptor densities. No significant correlation was
detected between the days on LVAD support to receptor density
(p=0.260).
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Figure 16. Muscarinic Receptor Kd. Kd values were found in
the radioligand binding assays. A 1-way ANOVA found no
significant change in Kd from NF to F samples. A significant
increase in Kd was found in the F+LVAD group versus control
(p<0.001).
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receptor densities. Statistical analysis found no significant correlation between the days
of LVAD support and receptor densities.
The radioligand binding assays measured total muscarinic receptor density as well as
receptor Kd. The Kds found for the three groups are depicted in Figure 16. No
significant differences were found when comparing NF and F groups, with Kds of 220.40
± 15.88 pM in F versus 161.10 ± 14.54 pM in control. The F+LVAD group had Kds of
289.40 ± 30.92 pM, resulting in a statistically significant increase in Kd versus control.

3.2 Percents of Muscarinic Receptor Subtypes in NF, F, and F+LVAD Tissue
Muscarinic receptor subtypes were measured in NF, F, and F+LVAD left ventricular
tissue. Thirty-six of the samples used to measure total muscarinic receptor densities were
also used to measure percents of muscarinic receptor subtypes using the time-dependent
competition binding assay (tissue from patients highlighted in grey on Table I). Once all
data was collected, the percent of each subtype was compared. The raw data results for
each subtype are depicted in Figures 17-20. The percent of M1 subtype, as shown in
Figure 17, was 15.63 ± 3.11 in NF tissue, 12,96 ± 3.15 in F, and 21.28 ± 1.96 in
F+LVAD. Although the percent of M1 appears to be lower in failure and increase back
up upon LVAD support, the differences did not reach statistical significance. The
percent of muscarinic receptor subtype M2 also did not change from NF to F or
F+LVAD. With percents of 61.60 ± 2.93 (NF), 60.19 ± 1.82 (F), and 62.86 ± 2.25
(F+LVAD), depicted in Figure 18, the percent of M2s stayed the same in each group.
Figure 19 shows the results of M3. The percent of M3 was 19.83 ± 3.73 in NF, 10.97 ±
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Figure 17. Percents of M1 Receptor Subtype (Raw Data).
Before normalizing to 100%, a 1-way ANOVA detected no
significant changes in the percents of M1 found in each group
(p=0.127).
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Figure 18. Percents of M2 Receptor Subtype (Raw Data).
Before normalizing to 100%, a 1-way ANOVA detected no
significant changes in the percents of M2 found in each group
(p=0.730).
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Figure 19. Percents of M3 Receptor Subtype (Raw Data).
Before normalizing to 100%, a 1-way ANOVA detected a
significant decrease in the percent of M3 receptor subtype in F
tissue compared to control (* p<0.05). A significant increase
§§
was found in the F+LVAD group versus the F group (
p<0.01).
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Figure 20. Percents of M4 Receptor Subtype (Raw Data).
Before normalizing to 100%, a 1-way ANOVA was performed
and detected no significant changes in the percents of M4 found
in each group (p=0.495).
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2.52 in F, and 24.89 ± 2.09 in F+LVAD. The percent of M3 did significantly decrease
from NF to F (p<0.05) and increase back up from F to F+LVAD (p<0.01). The percents
of M4 did not significantly change between the three groups. As shown in Figure 20, the
percents of M4 were 33.97 ± 2.93 in NF, 31.53 ± 2.75 in F, and 36.21 ± 2.60 in F+LVAD.
On a heart to heart analysis, the percents of M1, M2, M3, and M4 equated to a value not
equal to 100%. This was not a surprising find due to the four subtype selective
antagonists not being absolutely subtype selective. Because of this, it was also important
to normalize each heart to 100% and compare the results to the raw data. Figure 21
shows the percents of M1 once data was normalized to 100%. With percents of 12.03 ±
1.33 in NF, 9.97 ± 1.95 in F, and 14.47 ± 1.11 in F+LVAD, no statistically significant
differences were found between groups. Looking at the raw percents of M1 in Figure 17
and the normalized graph in Figure 21, both sets of data show a slight loss in failure and
increase back upon LVAD support. Figure 22, the normalized percents of M2, show
49.29 ± 2.75 in NF, 53.34 ± 3.29 in F, and 43.75 ± 1.20 in F+LVAD. Like the raw data
in Figure 18, no significant differences were found when comparing NF and F groups. A
difference only detected in the normalized data was the decrease in percent M2 upon
LVAD support compared to the percent in failure (p<0.05). The percent of M3s once
normalize, in Figure 23, revealed the same results as the raw data. There was a
significant decrease in the percent M3 in F (8.61 ± 1.65) versus NF (13.56 ± 2.16) with
recovery from failure upon LVAD support (16.65 ± 0.72). The percents of M4s
normalized also showed the same results as the raw results. Figure 24 shows the results
with 25.19 ± 0.93 in NF, 26.41 ± 0.67 in F, and 25.83 ± 1.37 in F+LVAD.
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Figure 21. Percents of M1 Receptor Subtype (Normalized Data).
After normalizing to 100%, a 1-way ANOVA was performed and
detected no significant changes in the percents of M1 found in
each group (p=0.124).
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Figure 22. Percents of M2 Receptor Subtype (Normalized Data).
After normalizing to 100%, a 1-way ANOVA was performed and
detected no significant changes in the percents of M2 from F to NF
tissue. A significant decrease in the percent M2 receptor subtype was
§
found in the F+LVAD group versus the F group ( p<0.05).
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Figure 23. Percents of M3 Receptor Subtype (Normalized Data).
After normalizing to 100%, a 1-way ANOVA detected a significant
decrease in the percent of receptor subtype M3 in the F group versus
control (* p<0.05) and a significant increase in the percent of
receptor subtype M3 in the F+LVAD group versus the F group
§§
( p<0.01).

52

M4 Receptors (%)

30

20

10

0
NF
n=11

F
n=12

F + LVAD
n=12

Figure 24. Percents of M4 Receptor Subtype (Normalized Data).
After normalizing to 100%, a 1-way ANOVA was performed and
detected no significant changes in the percents of M4 found in each
group (p=0.714).
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It was difficult to make conclusions about each receptor subtype in failure and with
mechanical unloading for several reasons. First, the technique used only produced the
percent of each subtype in LV samples, not the density. While making conclusions about
the percent of each subtype is sufficient, the potential change in subtype density may not
mirror the same differences. Also, the lack of absolutely subtype selective antagonists
for these subtypes made it more difficult to interpret the data. Because M1 and M3
subtypes couple to the same G protein and stimulate the same signaling pathway, the
percent of these two subtypes together were also determined for each group. Figure 25
shows these results. It was found that the percent of M1 + M3 was 26.82 + 2.28 in NF,
20.25 ± 2.94 in F, and 31.11 ± 1.35 in F+LVAD. The percent of these odd-numbered
subtypes did not significantly change in failure versus control. Upon LVAD support, the
percent of M1 + M3 significantly increased versus failure. M2 and M4 couple to the same
G protein and stimulate the same signaling pathway, therefore the percent of these
subtypes together were also determined for each group. as shown in Figure 26, the
percent of M2 + M4 were 73.24 ± 2.31 in NF, 79.75 ± 2.94 in F, and 68.89 ± 1.35 in
F+LVAD. No significant differences were found between NF and F groups. Upon
LVAD support, there was a significant decrease in the percent of M2 + M4 versus the
percent in failure.

3.3 Muscle Function Analysis
Table II shows the patient population used to study muscle function on fresh cardiac
muscles of the left ventricle. Twenty patients were used, including 11 representing NF
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Figure 25. Percents of M1 and M3 Receptor Subtypes. M1 and
M3 receptor subtypes couple to Gq proteins to elicit the same
downstream signaling pathway. Percents of these oddnumbered subtypes were added together on a heart-by-heart
basis and a 1-way ANOVA found no significant change in these
receptor subtypes in F tissue versus NF tissue, but a significant
§§
increase in F+LVAD versus F tissue ( p<0.01).
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Figure 26. Percents of M2 and M4 Receptor Subtypes. M2 and
M4 receptor subtypes couple to Gi proteins to elicit the same
downstream signaling pathway. Percents of these evennumbered subtypes were added together on a heart-by-heart
basis, and a 1-way ANOVA found no significant change in
these receptor subtypes in F tissue versus NF tissue, but a
§§
significant decrease in F+LVAD versus F tissue ( p<0.01).
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Table II. Characteristics of Patients Used in Muscle Function Studies.
Left ventricular (LV) tissue samples were taken from 20 patients, 11
representing NF tissue and 9 representing F tissue. Ages ranged from 3974 years with both males (M) and females (F) included in the experiment.
Ejection fractions needed to be ≥50% in the NF tissue and ≤35% in the F
group. Common medications taken by each patient are listed above.
(Abbreviations: MET = Metoprolol, CAP = Captopril, AM = Amiodarone,
LIS = Lisinopril, DIG = Digoxin, EPI = Epinephrine, MIL = Milrinone,
CARV = Carvedilol, NE = Norepinephrine)
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tissue and 9 HF patients. The ages of patients studied ranged from 39-74 years old with
both males and females included in the study. Ejection fractions were greater than 50%
in all NF tissue and less than 35% in HF patients. Common medications used by each
patient included β-blockers, ACE inhibitors, and inotropes.
Before adding acetylcholine (ACh) or isoproterenol (ISO) to the muscles, the six
contractile parameters were recorded for both time control and drug-treated muscles.
Table III and Table IV represent the baseline results. When comparing all NF muscles
(time control and ACh-treated) to F muscles (time control and ACh-treated), initial
differences were found in developed tension, time to peak tension, and time to half
relaxation. This is not surprising because failing tissue has been found to have less
contractile abilities than non-diseased cardiac tissue. Table IV compares the baseline
contractile parameters of time control versus ACh-treated muscles in each group. No
differences were found for any of the six contractile parameters. This baseline data
ensures that differences found between time control and drug-treated muscles was due
strictly to the doses of ACh or ISO and not by differences in quality of the muscle.
Dose-Response Curves Upon Additions of ACh
The contractile parameters were recorded after addition of each ACh dose. For each
parameter, comparisons were made between time control and ACh muscles in each
sample group and comparing the addition of ACh between NF and F groups.
Figure 27 shows the resting tenstion (RT) results with addition of ACh. At all six
doses, no significant differences were found when comparing NF time control to NF
ACh-treated, F time control to F ACh-treated, or NF ACh-treated to F ACh-treated.
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Table III. Baseline Contractile Parameters in NF and F Muscles.
Baseline contractile parameters were compared in NF and F tissue
groups. no significant changes in RT, +dT/dt, or –dT/dt were
detected from F to NF groups. Significant decreases were found in
DT (p<0.05), TPT (p<0.001), and THR (p<0.001) in failure versus
non-diseased tissue.
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Table IV. Baseline Contractile Parameters in Muscles to be
Treated with ACh and Those Muscles Serving as Time
Control (TC). NF and F tissue was divided into muscles that
would be treated with doses of ACh and those to serve as a
control. Before the experiment, contractile parameters were
compared between the ACh-treated muscles and TC muscles in
both tissue types. No significant differences were found in
either tissue group.
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Figure 27. Dose-Response to ACh – Resting Tension (RT) Results.
No significant changes were found between NF muscles treated with
ACh and those serving as time control (TC) [top graph]. No significant
changes were found between F muscles treated with ACh and those
serving as TC [middle graph]. No significant differences were detected
in the percent change of RT in ACh-treated F muscles verses AChtreated NF muscles [bottom graph].
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Figure 28. Dose-Response to ACh – Developed Tension (DT) Results. No
significant changes were found between NF muscles treated with ACh at lower
doses and those serving as time control (TC), however addition of the two
highest doses of ACh resulted in a significant recovery in the percent change of
DT compared to control [top graph] (p<0.001). No significant changes were
found between F muscles treated with ACh at lower doses and those serving as
TC, however addition of the two highest doses of ACh resulted in a significant
recovery in the percent change of DT compared to control [middle graph]
(**p<0.01; ***p<0.001). No significant differences were detected in the percent
change of DT in ACh-treated F muscles verses ACh-treated NF muscles [bottom
graph].
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The results for developed tension (DT) are depicted in Figure 28. NF muscles treated
with ACh at lower doses (1, 10, and 100 nM and 1 µM) produced no change in DT
compared to time control. When 10 µM and 100 µM of ACh were added, treated
muscles significantly recovered their percent change in DT compared to time control (10
µM: -10.50 vs -23.10 (p<0.001); 100 µM: -6.90 vs -25.35 (p<0.001)). The middle
graph shows the same comparison, but with the F tissue group. Again, the two highest
doses of ACh showed a significant recovery in DT compared to the time control muscles
(10 µM: -4.96 vs -15.44 (p<0.01); 100 µM: -3.12 vs -19.45 (p<0.001)), while the four
lower doses of ACh produced no change in response compared to control. The response
of ACh addition was compared between the two groups of tissue as well. ACh doses
elicited the same effect at all six doses in both NF and F muscles, with no significant
changes in their DT found.
Time to peak tension (TPT) was the next parameter compared. In Figure 29, no
significant differences were found between time control and ACh-treated muscles in NF
tissue and F tissue. Figure 29 also shows the comparison of ACh addition in NF tissue
versus ACh addition in F tissue. While the NF muscles continue to decrease from
baseline upon each dose addition, F muscles preserve their TPT, with values closely
mimicking baseline values at all six doses. Here, 1, 10, or 100 nM of ACh did not
significant change the TPT between F and NF muscles. At 1 µM, F muscles had a
percent change in TPT of -0.40 and NF muscles -3.94; a statistically significant change
found (p<0.05). Differences were also detected at 10 µM and 100 µM ACh-treatments
(10 µM: -0.08 (F) vs -3.39 (NF) (p<0.05); 100 µM: 0.13 (F) vs -3.90 (NF) (p<0.01)).
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Figure 29. Dose-Response to ACh – Time to Peak Tension (TPT) Results.
No significant changes were found between NF muscles treated with ACh and
those serving as time control (TC) [top graph]. No significant changes were
found between F muscles treated with ACh and those serving as TC [middle
graph]. Significant differences were detected in the three highest doses of
ACh in F tissue versus NF tissue [bottom graph] (*p<0.05; **p<0.01).

64

Time to Half Relaxation
(%Change from Baseline)

2
1
0
-1
-2
-3
-4
-10

NF-TC
NF-ACh
-9

-8

-7

-6

-5

-4

-3

-4

-3

-4

-3

Time to Half Relaxation
(%Change from Baseline)

Acetylcholine (log M)

3
2
1
0
-1
-2
-3
-10

F-ACh
F-TC
-9

-8

-7

-6

-5

Time to Half Relaxation
(%Change from Baseline)

Acetylcholine (log M)

4
2
0
-2
-4
-10

F-ACh
NF-ACh
-9

-8

-7

-6

-5

Acetylcholine (log M)

Figure 30. Dose-Response to ACh – Time to Half Relaxation (THR) Results.
No significant changes were found between NF muscles treated with ACh and
those serving as time control (TC) [top graph]. No significant changes were found
between F muscles treated with ACh and those serving as TC [middle graph]. No
significant differences were detected in the percent change of THR in ACh-treated
F muscles verses ACh-treated NF muscles [bottom graph].
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Figure 31. Dose-Response to ACh – Peak Rate of Tension Rise (+dT/dt) Results.
Significant differences were found between NF muscles treated with the two highest
doses of ACh and those serving as time control (TC) [top graph] (*p<0.05;
**p<0.01). No significant changes were found between F muscles treated with ACh
and those serving as TC [middle graph]. No significant differences were detected in
the percent change of +dT/dt in ACh-treated F muscles verses ACh-treated NF
muscles [bottom graph].
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Figure 30 shows the time to half relaxation (THR) results. No significant changes
were detected between time control and ACh muscles of NF tissue or time control and
ACh muscles of F tissue (shown in Figure 30a and 30b). NF and F tissue, with addition
of ACh, did not produce any significant changes at any of the six doses either.
The results of peak rate of tension rise (+dT/dt) were compared in Figure 31. In NF
tissue, the time control muscles continually decreased in percent with time, while those
treated with ACh recovered toward baseline +dT/dt values as the concentration of ACh
increased. With the addition of 10 µM ACh, ACh-treated NF muscles had a percent
change +dT/dt of -2.96 while time control NF muscles had a percent change +dT/dt of 16.41, a significant change in response (p<0.05). Upon addition of 100 µM ACh, NF
muscles had a percent change +dT/dt of -0.40 versus the time control NF muscles of 16.27 (p<0.01). This resulted in a significant increase of +dT/dt with the two most
concentrated doses of ACh versus control. The F tissue, depicted in Figure 31(middle
graph), trended similarly to the NF tissue, however no significant changes were detected.
In comparing the addition of ACh between NF and F tissue, no significant differences
were found.
–dT/dt, shown in Figure 32, show the same changes as +dT/dt. When comparing NF
time control to NF ACh, the two highest doses of ACh resulted in a significant increase
in

-dT/dt versus control (10 µM: -4.24 (ACh-treated) vs -18.13 (control) (p<0.01);

100 µM:

-1.32 (ACh-treated) vs -19.26 (control) (p<0.001). In comparing F time

control to F ACh and ACh addition in NF and F tissue, no significant changes occurred in
respect to –dT/dt.
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Figure 32. Dose-Response to ACh – Peak Rate of Tension Fall (-dT/dt) Results.
Significant differences were found between NF muscles treated with the two
highest doses of ACh and those serving as time control (TC) [top graph] (*p<0.05;
**p<0.01). No significant changes were found between F muscles treated with
ACh and those serving as TC [middle graph]. No significant differences were
detected in the percent change of -dT/dt in ACh-treated F muscles verses AChtreated NF muscles [bottom graph].
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Addition of Isoproterenol (ISO)
One dose of the β-AR agonist ISO was added to both time control and ACh-treated
muscles after the ACh dose-response experiments were completed. Results are expressed
as the mean percent change from a time immediately before addition of ISO.
The RT results upon addition of ISO are depicted in Figure 33. Time control and
ACh-treated muscles had significantly different RTs from failing to non-failing groups
(TC: -3.9 vs -11.52, p<0.001; ACh: -3.9 vs -9.3, p<0.01). Non-failing muscles had
comparable RTs in ACh-treated muscles compared to control (-9.3 vs -11.5) and failing
muscles had comparable RTs in ACh-treated versus control groups (-3.9 vs -3.9).
Figure 34 represents DT data collected upon addition of ISO. Time control muscles
had a significantly lower percent change in DT in failing versus non-failing tissue (127.5
vs 191.6, p<0.01). ACh-treated muscles also had a significantly lower percent change in
DT in failing versus non-failing tissue (47.9 vs 109.8, p<0.001). Looking at the change
in non-failing tissue, there was ~43% decrease in DT in ACh-treated muscles compared
to control (109.8-191.6 / 191.6 = 42.7%). In failing tissue, there was ~62% decrease in
DT in ACh-treated muscles compared to control (47.9-127.5 / 127.5 = 62.4%).
Therefore, failing tissue had a greater negative response to DT by approximately 19%.
TPT, depicted in Figure 35, significantly changes between sample groups and
between drug treatment. There was a significantly greater change in TPT in non-failing
muscles than failing muscles for both time control and ACh-treated groups (time control:
-36.9 in non-failing; -18.3 in failing) (ACh-treated: -28.0 in non-failing; -12.4 in failing).
Looking at non-failing tissue only, there was a significant difference in the percent
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Figure 33. Resting Tension (RT) – Isoproterenol (ISO) Response.
Both time control (TC) and ACh-treated muscles had a significantly
less percent change in F tissue versus NF tissue after addition of
ISO (** p<0.01; *** p<0.001). Addition of ACh had no significant
change in the effect of ISO in NF or F groups.
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Figure 34. Developed Tension (DT) – Isoproterenol (ISO) Response.
Both time control (TC) and ACh-treated muscles had a significantly
less percent change in F tissue versus NF tissue after addition of ISO
(** p<0.01; *** p<0.001). Addition of ACh significantly decreased the
percent change in DT in NF tissue (43% decrease) and F tissue (62%
§§§
decrease) compared to muscles only treated with ISO ( p<0.001).
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Figure 35. Time to Peak Tension (TPT) – Isoproterenol (ISO) Response.
Both time control (TC) and ACh-treated muscles had a significantly less
percent change in F tissue versus NF tissue after addition of ISO
(***p<0.001). Addition of ACh significantly decreased the percent change
in TPT in NF tissue and F tissue compared to muscles only treated with ISO
§§§
§§
( p<0.001; p<0.01).
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Figure 36. Time to Half Relaxation (THR) – Isoproterenol (ISO) Response.
Time control (TC) and ACh-treated muscles had no significant percent change in
F tissue versus NF tissue after addition of ISO. Addition of ACh significantly
decreased the percent change in THR in F tissue compared to muscles only
§§
treated only with ISO ( p<0.01). Addition of ACh did not significantly change
in THR in NF tissue versus TC.
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change of TPT from ACh-treated muscles versus time control (-28.0 vs -36.9). Also, the
percent change in TPT was significantly different in failing versus non-failing tissue (12.4 vs -18.3).
The next contractile parameter analyzed was THR. As shown in Figure 36, THR in
time control muscles did not significantly change in failing tissue versus control (-26.7 vs
-23.3). ACh-treated muscles also did not significantly change in failing versus nonfailing muscles (-16.2 vs -18.1). THR was comparable in non-failing and ACh-treated
muscles (-23.3 and –18.1) while THR in failing muscles was significantly different in
ACh-treated versus time control muscles (-16.2 vs -26.7).
+dT/dt, in Figure 37, did not significantly change when comparing ACh-treated
muscles in failing versus non-failing groups (37.5 vs 116.7). There was a significant
percent change in +dT/dt in time control muscles comparing failing to non-failing tissue
(112.0 vs 253.7, p<0.001). Both non-failing and failing muscles did significantly change
in +dT/dt when comparing ACh-treated to time control muscles (non-failing: 116.7 v
253.7, p<0.001; failing: 37.5 vs 112.0, p<0.05).
-dT/dt, shown in Figure 38, did not significantly change when comparing ACh-treated
muscles in failing versus non-failing groups (37.2 v 94.6). There was a significant
percent change in –dT/dt in time control muscles comparing failing and non-failing tissue
(114.2 vs 215.3, p<0.01). Both non-failing and failing muscles did significantly change
in –dT/dt when comparing ACh-treated to time control muscles (non-failing: 94.6 vs
215.3, p<0.001; failing: 37.2 vs 114.2, p<0.05).
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Figure 37. Peak Rate of Tension Rise (+dT/dt) – Isoproterenol (ISO) Response.
Time control (TC) muscles had significantly less of a response in F tissue versus NF
tissue to ISO (*** p<0.001). Addition of ACh significantly decreased the +dT/dt in
§§§
§
F and NF muscles versus their respective TC group ( p<0.001; p<0.05).
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Figure 38. Peak Rate of Tension Fall (-dT/dt) – Isoproterenol (ISO) Response.
Time control (TC) muscles had significantly less of a response in F tissue versus
NF tissue to ISO (** p<0.01). Addition of ACh significantly decreased the -dT/dt
§§§
§
in F and NF muscles versus their respective TC group ( p<0.001; p<0.05).
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CHAPTER IV
DISCUSSION

4.1 Effect of Total Muscarinic Receptor Density and Affinity in Failure and Upon
LVAD Support
ANS imbalance is a characteristic in HF. The SNS has been the focus of research for
the past 20+ years, resulting in definitive conclusions about its role in failure. With the
consensus that the SNS is overactivated in HF, leading to a significant downregulation of
β-ARs, new drug therapies targeting β-ARs were introduced. Research on the PNS in HF
has led to conflicting results, allowing for no consensus to be reached and potential
therapies targeting the PNS disregarded. Muscarinic receptor densities have been studied
in various models of HF, however inconsistent findings have led to more confusion and
less conclusions about the PNS in HF.
Some early studies of muscarinic receptors report a significant decrease in receptor
density in failure. Vatner et al in 1988 used left ventricular sarcolemma from mongrel
canines to measure muscarinic receptor densities. With control (n=10) and HF (n=8)
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they found densities to be significantly reduced (3.6 ± 0.4 versus 5.6 ± 0.6 pmol/mg,
p<0.05) in the canine model of HF56. Mertens et al used rat left ventricular tissue (n=6
per group) to determine a significant decrease in muscarinic receptor density compared to
control (221.0 ± 8.9 versus 308.8 ± 16.1 fmol/mg, p<0.05)37.
The first human studies on muscarinic receptor densities found no significant changes
between non-failing and failing tissue. Bohm and colleagues used 16 patients with DCM
and coronary artery disease (CAD), aged between 21-59 years, against 5 controls (22-31
years old). They found no significant change in receptor density (275 ± 21 versus 211 ±
22 fmol/mg in failure)3. A review in 1999 by Giessler and others highlighted the work
done on muscarinic receptors up to that time. Their own research examined muscarinic
receptor density in right atrium and left ventricle tissue. The densities did go up in HF
(n=11) compared to control (n=5) but not enough to be statistically significant. It is
important to point out that in this case, 5 control hearts came from patients with a mean
age of 33 years old while the 11 HF patients had a mean age of 51 years old19.
Coinciding with our current findings, researchers in France used positron emission
tomography (PET) to find a significant upregulation of muscarinic receptor density in HF
patients (n=20) compared to control (n=12) (p<0.005)32. Wilkinson and colleagues
examined atrial and ventricular muscarinic receptor densities in a canine model of HF.
No significant differences in density were found in the atrium but a significant increase in
muscarinic receptor density was found in the left ventricular HF model. Using n=4 (HF)
versus n=6 (control), they found densities to be 245.0 ± 25.0 fmol/mg protein in failure
compared to 160.0 ± 10.0 fmol/mg in control (p<0.01)60. Vatner et al also found a
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significant increase in muscarinic receptors in the pacing model of HF. Canines with HF
were found to have densities 153.0 ± 6.2 fmol/mg versus 124.0 ± 7.4 fmol/mg in control.
Vatner et al had previously found a significant decrease in muscarinic receptor density in
a canine model of HF (induced by aortic banding) and stated that differences found
between these experiments were due to differing models of HF57.
This current study was aimed to clarify the conflicting results generated by the past
twenty years of research on muscarinic receptors in relation to HF. Several differences
from previous studies to this current study include the model being tested, age, and
sample size. Model differences may factor in differing results because muscarinic
receptor densities may be different among species. Also, animal models do not form HF
over a prolonged, natural time course. The difference in disease acquisition may add to
conflicting muscarinic receptor density findings. Age is also an important factor in
choosing a sample population, especially when measuring muscarinic receptors. It is
established that muscarinic receptor density is significantly decreased as age increases,
therefore, studies with large differences in age may not appropriately respresent
muscarinic receptor density6. Finally, sample sizes may contribute to differing
conclusions. With a small sample size, such as five, differences in density are more
difficult to detect.
With a large sample selection of human hearts from patients with a similar mean age,
this study found total muscarinic receptor density to be significantly upregulated in the
failing heart (275.8 ± 11.9 vs 194.1 ± 17.3 fmol/mg (p<0.01)) and even more
significantly upregulated upon LVAD support compared to control (315.8 ± 11.9,
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p<0.001). A significant increase in receptor density may be opposing β-AR stimulation
by inhibiting the adenylyl cyclase, cAMP pathway that is overactivated in the failing
human heart. Because M2 receptors are predominant, and they act by inhibiting this
pathway, an increase in density may be a mechanism for reducing sympathetic
overstimulation. Upons LVAD support, muscarinic receptors remain upregulated
compared to control. β-AR densities recover with LVAD support, having densities after
an LVAD mimicking non-failing values, therefore, our findings on tissue with LVAD
support are surprising42. Although the reason why muscarinic receptor densities remain
upregulated in LVAD remains unknown, one could speculate that it is in response to an
increase in β-AR density.
An upregulation of muscarinic receptor density in failure is clear, and is further
supported by previous studies that found Gi protein, that which couples M2/4 receptors,
also upregulated in failure2,17,57. This increase in Gi provides evidence that the effects
regulated by M2/M4 receptors are increased in HF2. M2/4 receptors inhibit AC, cAMP
pathway using Gi only when the pathway is turned on by the SNS. During failure, the
PNS may act to increase opposition of established SNS overstimulation by increasing the
amount of muscarinic receptors. More muscarinic receptors coupled to Gi would be able
to inhibit the overactivated SNS.
PNS activity on the heart is regulated at various levels, therefore muscarinic receptor
density and Gi protein levels alone cannot be the answer to PNS control on the heart.
Although muscarinic receptors act as the target of the PNS on cariomyocytes, the vagus
nerve is an important regulator of the PNS and is found to have diminished control in
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HF61. Recent studies have found vagal nerve stimulation to increase survival and
improve autonomic balance in animal models of HF61. No current study has performed
vagal nerve stimulation and then measured muscarinic receptor density on
cardiomyocytes, although it would be interesting to see if stimulation of the vagus nerve
produces changes on receptor density.
When looking at antagonist affinity to muscarinic receptors, this current study found
no significant change in affinity between NF and F groups. However, a significant loss
in affinity was found in F+LVAD versus control. Our findings in NF and F human hearts
were in agreement to other studies that found no change in affinity between
groups3,32,56,57. To our knowledge, this is the first study to measure muscarinic receptors
upon LVAD support, therefore the only study to find changes in affinity. LVADs have
been shown to recover remodeling in the failing heart, including restoring β-AR density
to NF values. A possible reason the antagonist affinity decreases upon LVAD support
may be because a significant increase in receptor stimulation is no longer necessary.
Receptors may conformationally change or desensitize in response to SNS regulation.

4.2 Muscarinic Subtypes in the Non-failing, Failing, and LVAD Human Hearts
The functional role of muscarinic receptor subtypes was not realized until the 1990s58.
In the heart, M2 was accepted as the only functional subtype until studies on rats, chicks,
canines, and other species found non-M2 subtypes existing52,58. The first human study to
detect multiple muscarinic receptor subtypes in the heart was published in 200158.

81

In this current study, we were able to support the idea that there are multiple
muscarinic receptor subtypes in the NF, F, and F + LVAD support human heart. Using
non-labeled subtype selective antagonists at established Ki concentrations, we were able
to fraction subtypes in our three sample populations. Because each heart resulted in a
percent binding over 100%, we chose to interpret the raw data and to normalize the data
to 100%.
When looking at the raw data, we found no significant change in the percent of M1,
M2, or M4 between NF, F, and F+LVAD. The percent of M3 significantly decreased in
failure compared to control and significantly increased back up to NF results upon LVAD
support. When looking at the normalized data, we found no significant change in the
percent of M1 or M4 between NF, F, and F+LVAD groups. The same change in the
percent of M3 was found once normalized, significantly decreasing in failure compared to
control and significantly increasing back to NF results upon LVAD support. The one
difference between the normalized and raw data was with the percent of M2. When
comparing NF to F groups, the percents did not significantly change in either
representation of the data. However, once normalized there was found to be a significant
decrease in the percent of M2 upon LVAD support compared to control, a difference not
detected in the raw data.
The percents of M1, M2, and M4 did not change significantly between the groups
tested, although a change in receptor density should not be disregarded. We do not know
how the densities of each subtype change in response to failure or LVAD support,
however with data we have found, we can speculate about how the subtypes may change
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in density. For example, we know total muscarinic receptor density is upregulated both
in F and F+LVAD support compared to NF tissue. We may speculate that the
predominant subtypes, M2 and M4, which are also the receptors coupled to the inhibitory
Gi protein, increase in density while the density of M1 and M3 stay the same,
respectively. This speculation could result in the percent of M2 and M4 staying the same,
with a slight decrease in the percent of M1 and M3 (significant enough for M3 because the
percent in the left ventricle is only a small fraction of the whole). This is one possible
mechanism to explain total density increasing with percents changing as described above,
although other mechanisms are also possible.
Our study was the first to measure the percent of muscarinic subtypes in NF, F, and
F+LVAD tissue; however researchers have examined the idea of multiple subtypes
existing in the non-diseased human heart. Huizen Wang and colleagues used multiple
experimental techniques to detect muscarinic receptor subtypes. They performed
competition binding studies using pirenzepine, methoctramine, 4-DAMP, and
tropicamide to detect the percent binding of antagonists to receptor subtypes. Their data
found (in %) 30.3 ± 10.4 using pirenzepine, 78.2 ± 9.8 with methoctramine, 15.4 ± 2.5
for 4-DAMP, and 18.7 ± 8.4 using tropicamide. Unlike our current study, Want et al
performed competition binding studies with varying doses of each non-labeled subtype
selective antagonist, while we kept the antagonist concentration constant and varied the
time of incubation. By varying the concentration of selective antagonists, they were able
to yield pKi values. Using previous literature and established pKi values for each
subtype binding to antagonists, these researchers concluded that pirenzepine was binding
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to M1 receptors, methoctramine to M2, 4-DAMP to both M3 and M1, and tropicamide to
M3 and M2. Therefore, they detected the presence of M1, M2, and M3 receptors using
competition binding experiments. They also used reverse-transcriptase polymerase chain
reaction (RT-PCR), Western blotting, and confocal microscopy to examine the
muscarinic receptor subtypes. Results from Western blotting and confocal microscopy
supported the presence of M1, M2, M3, and M5 subtypes. Neither technique was able to
detect M4. RT-PCR, on the other hand, detected the presence of mRNA for all five
subtypes58.
More recently, Perez and others examined the existence of non-M2 subtypes in the
human heart using immunoblotting, ELISA, and RT-PCR. All three experimental
techniques supported the idea that all 5 muscarinic receptor subtypes are present in
human atrial and ventricular tissue. They further suggest that these subtypes are able to
act as non-interacting monomers and interacting oligomers46.
With multiple subtypes existing in the human heart, multiple signaling pathways and
elicited responses must be present. In the ventricles, M2 and M4 subtypes couple to the
inhibitory Gi protein. Upon activation, Gi inhibits adenylyl cyclase which decreases
levels of cAMP and PKA activity. This effects Ca++-cycling proteins on the SR,
producing a negative chronotropic and inotropic effect on the heart. M1, M3, and M5
activate stimulatory pathways and are coupled to Gq proteins. Upon activation, PLC is
stimulated which cleaves phosphatidylinositol bisphosphate (PIP2) into IP3 and DAG.
Recently, Kitazawa et al used mice atria to demonstrate a positive inotropic response
upon activation of M3.
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4.3 Muscle Function
Muscle function experiments were performed to see if a relationship existed between
total muscarinic receptor density differences in non-failing and failing hearts and the
functional response of cardiac muscle. We speculated that, because a significant increase
in muscarinic receptor density exists in failing tissue, the negative inotropic and
chronotropic effects on the heart would be greater in failure.
Baseline parameters were measured to ensure that differences found in the six
contractile parameters were due to drug responses and not to initial differences in muscle
function. As shown in Table III, failing tissue was found to have significantly decreased
developed tension (DT), time to peak tension (TPT), and time to half relaxation (THR)
than the non-failing groups. This phenomenon has been shown in previous work,
indicating that failing tissue is weaker than healthy, non-diseased hearts. Because of
differences in the contractile function of tissue groups, data was represented as a percent
change from baseline. Muscles within each group were also analyzed at baseline. Table
IV shows that time control and ACh-treated muscles began at comparable contractile
measurements in both non-failing and failing groups.
Looking at the resting tension (RT) contractile parameter upon addition of ACh doses,
this parameter does not significantly change between non-failing and failing muscles
treated with ACh, or when comparing non-failing time control and ACh muscles, and
failing time control and ACh-treated muscles (shown in Figure 24). RT is the amount of
tension generated while the muscle is not contracting. Because RT does not require
stimulation of contraction or is in response to muscarinic stimulation, this lack of changes
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found is not surprising. These results do demonstrate the loss in RT, with or without
ACh-treatement – as a result of time.
Developed tension (DT) is one of the most important of the six contractile parameters
measured because it is the tension produced from a muscle’s resting state to the highest
point of contraction. DT is a direct measure of muscle function and how well the muscle
is contracting. As shown in Figure 25, lower doses of ACh produce no change in DT
compared to control. However, when higher doses of ACh were added, DT recovered
compared to control in both non-failing and failing tissue. Because this dose-response
curve was in the absence of β-AR stimulation, higher doses of ACh could be stimulating
the less predominant muscarinic receptor pathway (M1/M3/M5). If this were true, these
muscarinic receptors would stimulate Ca++ movement within cells, causing a positive
response to ACh. It is important to note that, although the two highest doses of ACh
elicit recovery in DT in both groups, their response is still negative compared to baseline
measures. If these higher doses were added initially, they may or may not have produced
a positive response on DT. Also, when looking at ACh-treated muscles in failing versus
non-failing tissue, no statistically significant differences were found. Therefore, ACh
without stimulation of β-AR signaling did not change how well the muscle was
contracting in failing hearts versus non-failing hearts.
One of the timing parameters, time to peak tension (TPT), did not shown significant
differences when comparing time control and ACh-treated muscles in each group. The
percent change from baseline declined as time increased in both time control and AChtreated muscles in the healthy heart. Failing tissue did not decline as great as non-failing
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tissue, yet time control and ACh muscles produced the same effect. When comparing
ACh addition in failing to non-failing muscles, TPT significantly recovered to baseline in
failing tissue while non-failing tissue continued to decline as ACh doses increased.
Another timing parameter, time to half relaxation (THR), showed no changes between
muscle types or between non-failing and failing ACh-treated muscles. However, a high
amount of variability may restrict differences from being found.
The peak rate of tension rise (+dT/dt) is the point where the muscle is contracting the
fastest and the peak rate of tension fall (-dT/dt) is the point where the muscle is relaxing
the fastest. Neither of these parameters changed in time control or ACh-treated failing
muscles nor did they differ when comparing failing ACh-treated muscles to non-failing
ACh-treated muscles. For both of these parameters, non-failing muscles treated with
ACh at higher doses showed significant recovery compared to the non-failing time
control muscles.
Adding ISO to all of the muscles at the end of the experiment allowed us to see the
affect ACh had on muscles with sympathetic stimulation. Most of the contractile
parameters (all except for THR) elicited changes between failing and non-failing tissue, a
response due to the difference in tissue type. ACh-treated muscles also produced
different responses compared to their time control counterparts in five of the six
contractile parameters (all except for RT).
Landzberg and colleagues examined left ventricular contractility in six normal patients
and seven patients 1-3 years after cardiac transplantation. In this study, patients were
infused with dobutamine, ACh, atropine, dobutamine + ACh, and dobutamine + atropine.
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Left ventricular +dP/dt was measured five minutes after each infusion and after addition
of a control (5% dextrose in water). Results show that left ventricular +dP/dt
significantly increases with addition of the β-AR agonist dobutamine. ACh, the
cholinergic agonist, alone did not produce a change in +dP/dt compared to control. When
ACh was infused with dobutamine, a small increase in +dP/dt was found. This work
shows that muscarinic stimulation or blockade modulates sympathetic activity,
demonstrating the important interactions of the SNS and PNS to regulate functional
responses of the heart30.
Another study, by Du et al, examined the effects of ACh and ACh with noradrenaline
on human right atrial and left ventricular trabeculae from 61 donor hearts. Similar to our
findings, results from this experiment indicated that ACh elicited an increase in
ventricular contractility at high doses. However, when ACh was added after prestimulation with noradrenaline, ACh decreased contractility. They also showed that
atropine blocked the positive inotropic response elicited by ACh alone and that these
responses did not change when propranolol was introduced15.

4.4 Summary
Total muscarinic receptor densities are upregulated in human HF. This result could be
in response to overactivated sympathetic stimulation. Because the inhibitory muscarinic
receptors, which take up approximately 80% of the total number of receptors, inhibit the
β-AR stimulated pathway, an increase in muscarinic receptors may be a compensatory
mechanism to antagonize the effects of the overstimulated SNS seen in HF. This theory
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is supported by previous studies that found a significant increase in Gi protein, that which
couples M2 and M4, in human HF2. In failing hearts with LVAD support, muscarinic
receptor densities remain significantly upregulated versus control, instead of showing
recovery to NF densities like β-ARs do upon LVAD support. This may or may not be
due to receptor subtype changes.
Muscarinic receptor subtypes differ in the G protein they couple, causing activation of
different signaling pathways. Even-numbered receptors couple Gi and produce a
negative inotropic and chronotropic effect while odd-numbered receptors couple to Gq
and produce a positive inotropic and chronotropic effect. Because multiple muscarinic
receptor subtypes exist that elicit opposite responses on the heart, the total density
differences found between groups may be a result of one, a few, or all subtype densities
changing. With the differences found in the percent of each subtype in the various tissue,
speculations may be made concerning the density differences of subtypes in each sample
group. Upon LVAD support, SNS balance has been found to be restored42. With
inhibitory receptor subtypes no longer needed in increased abundance, stimulatory
receptors may be synthesized more to increase their fraction of total muscarinic receptors
acting on cardiac myocytes.
The goal in investigating muscle function on NF and F tissue was to see if a
relationship existed between the functional response of fresh cardiac muscles and the
changes found in muscarinic receptor densities. In the dose-response curves, a significant
recovery was found when comparing higher doses of ACh to control muscles in both NF
and F tissue types (DT, TPT, +dT/dt, and –dT/dt results). With a lack of β-AR
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stimulation, M2 and M4 receptor pathways may only be signaling constitutively. M1, M3,
and M5, with high concentrations of a ligand, elicit a positive response on contractility –
resulting in the recovery seen in four of the contractile parameters. Once ISO is added,
M2 and M4 receptors are able to activate Gi and inhibit the AC-cAMP-PKA signaling
pathway to produce an inhibitory response. This is shown in DT, TPT, THR, +dT/dt, and
–dT/dt contractile parameters.
Through the radioligand binding assays, competition binding assays, and muscle
function analysis, it was shown that HF is associated with a significant increase in total
muscarinic receptor density, which remains upregulated with LVAD support. The
percent of M1-M4 receptor subtypes differed in the patient populations as well, showing
that muscarinic receptors play both an inhibitory and stimulatory role on heart rate and
force of contraction. The muscle function data supported the increase in total muscarinic
receptor densities relating to greater decreases in muscle contractility measures. In
conclusion, it is known that the overactivated SNS is a target of therapy in human HF –
which was found through years of research on its activity and signaling. β-ARs are a
target of medications that block the receptor from activating a stimulatory signaling
pathway. With findings from this current study and others, the role of the PNS may be
further investigated as a target for novel therapeutic approaches in tackling human HF.
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